Search academic texts

Information × Registration Number 0209U001823, 0106U012405 , R & D reports Title Innovation technologies in cancer treatment popup.stage_title Head Filonenko Valeriy, Registration Date 05-03-2009 Organization Institute of molecular biology & genetics popup.description2 Using SEREX methodology (serological identification of recombinant tumor-associated antigens) 40 genes of tumor-associated antigens of medullar breast carcinoma as potential targets for immunotherapy of cancer have been identified. For this purpose the modification of SEREX approach have been created. The modification was in depletion of total mRNA from tumor sample from genes of immunoglobulin Fc fragments. During the screening of phage cDNA library of tumors by autologous sera of cancer patient more then 70 positive clons was detected. Analysis of identified antigens have been performed. Number of chemical inhibitors of casein kinase (CK2) that is known target for anti-tumor therapy was synthesize. Using methods of computer modeling the model of interection between flavone derivatives and ATP acseptor site of CK2 kinase have been created. The created model made possible to go further for chemical optimization of flavone derivatives. As a consequence 11 new inhibitors of CK2 have been created withІС50 < 1 mM. Correlation between structure and inhibitor activity have been analyzed. The effect of modified plant alkaloid berberine - amitozynbereberin - on growth of model cell lines and tumors has been studied. Cytotoxyc and proapoptotic effect and the ability to prevent tumor growth have been detected. Product Description popup.authors popup.nrat_date 2020-04-02 Close